

September 2016 Vol.59 No.9:1216–1223 doi: 10.1007/s11426-016-0052-4

# Polyprenylated acylphloroglucinols from the fruits

Yang Liao<sup>1,2†</sup>, Shu-Ya Yang<sup>1,2†</sup>, Xiao-Nian Li<sup>1</sup>, Xing-Wei Yang<sup>1</sup> & Gang Xu<sup>1\*</sup>

of Hypericum henryi

<sup>1</sup>State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China

<sup>2</sup>University of Chinese Academy of Sciences, Beijing 100049, China

Received January 28, 2016; accepted April 20, 2016; published online August 1, 2016

Hyphenrones R–X (1–7), seven new polyprenylated acylphloroglucinols derivatives, were isolated from the fruits of *Hypericum henryi*, together with eight know analogues. Compounds 1 and 2 were elucidated to possess complex caged skeleton, while compounds 3-6 shared a common 3,9-epoxy moiety deriving from the normal polyprenylated acylphloroglucinols with a bicyclo[3.3.1]nonane-2,4,9-trione core. The new structures were elucidated on the basis of the interpretation of nuclear magnetic resonance (NMR) data, circular dichroism (CD) comparison, and single-crystal X-ray diffraction. In the bioassay, several compounds exhibited inhibitory activities against human tumor cell lines *in vitro*.

polyprenylated acylphloroglucinols, Hypericum henryi, hyphenrones R-X, antitumor

Citation: Liao Y, Yang SY, Li XN, Yang XW, Xu G. Polyprenylated acylphloroglucinols from the fruits of *Hypericum henryi*. Sci China Chem, 2016, 59: 1216–1223, doi: 10.1007/s11426-016-0052-4

## 1 Introduction

ARTICLES

· SPECIAL ISSUE · Natural Product Chemistry

Polycyclic polyprenylated acylphloroglucinols (PPAPs), reported only from the plants of family Guttiferae, are a group of structurally fascinating natural products possessing highly oxygenated acylphloroglucinol core and densely substituted with prenyl or geranyl side chains [1–3]. They exhibit a broad range of biological activities including anti-inflammatory, antibacterial, and antitumor effects, as well as central nervous system effects such as antidepressant and memory-enhancing properties [1,4]. Biogenetically, PPAPs are derived from a "mixed" mevalonate/methylerythritol phosphate and polyketide biosynthetic pathway [1,5,6]. Their acylphloroglucinol core structure is produced by a characteristic polyketide-type biosynthesis involving the condensation of one acyl-CoA and

three malonyl-CoA units [1,5,6]. Prenylation of this core structure affords monocyclic polyprenylated acylphloroglucinols (MPAP), which may be further cyclized to PPAP-type metabolites with diverse carbon skeletons [1,7].

*Hypericum henryi* H. Lév & Vaniot (Guttiferae) is a traditional Chinese medicinal plant used for the treatment of hepatitis and "dampness-heat" disease [8]. Previous phytochemical investigations on the aerial parts (excluding the fruits) of this plant have led to the characterization of numbers of PPAPs with diverse carbon skeletons [7,9,10]. In order to explore the chemical constituents of its fruits and further compare the difference of PPAPs from the mentioned two botanic parts, the phytochemical research on the fruits was carried out. As a result, seven new PPAPs (hyphenrones R–X, 1–7) were isolated (Scheme 1), together with eight know analogues: 3-hydroxyhyperforin-3,9-hemi-ketal (8) [11], furohyperforin [12], uralodin A [13], plukenetione B [14], hyphenrone M [7], hyphenrone N [7], tomoeone A [15], and

<sup>†</sup>The authors contributed equally to this work.

<sup>\*</sup>Corresponding author (email: xugang008@mail.kib.ac.cn)

<sup>©</sup> Science China Press and Springer-Verlag Berlin Heidelberg 2016



Scheme 1 Structures of compounds 1-8.

tomoeone E [15]. Our finding suggested that the carbon skeletons of the obtained PPAPs from the fruits showed great similarity with those of PPAPs from aerial parts, which indicated that the fruits could be used as another source of PPAPs. Herein, we report the isolation, structural elucidation, and the bio-evaluation of these new metabolites.

## 2 Experimental

#### 2.1 General experimental procedures

Melting points were obtained on an X-4 micro melting point apparatus. Optical rotations were measured on a Jasco P-1020 polarimeter (Japan). UV spectra were recorded on a Shmadzu UV-2401PC spectrometer (Japan). IR spectra were recorded on a Bruker FT-IR Tensor-27 infrared spectrophotometer (Germany) with KBr disks. 1D and 2D nuclear magnetic resonance (NMR) spectra were recorded on a Bruker DRX-600 spectrometer (Germany) using tetramethylsilane (TMS) as an internal standard. Unless otherwise specified, chemical shifts ( $\delta$ ) are expressed in ppm with reference to the solvent signals. Electrospray ionization mass spectrometry (ESIMS) and high resolution electrospray ionization mass spectrum (HREIMS) data were acquired on Waters Xevo TQS and Waters AutoSpec Premier P776 mass spectrometers (USA), respectively. X-ray data were generated using a Bruker Apex Duo instrument (Germany). Semi-preparative high performance liquid chromatography (HPLC) was performed on an Agilent 1100 HPLC with a Zorbarx SB-C<sub>18</sub> (9.4 mm×250 mm) column (USA). Silica gel (100-200 and 200-300 mesh, Qingdao Marine Chemical Co., Ltd., China), and MCI gel (75–150  $\mu$ m, Mitsubishi Chemical Corporation, Japan) were used for column chromatography. Fractions were monitored by thin-layer chromatography (TLC, GF 254, Qingdao Marine Chemical Co., Ltd., China), and spots were visualized by heating silica gel plates immersed in H<sub>2</sub>SO<sub>4</sub> in ethanol.

#### 2.2 Plant material

The fruits of *H. henryi* were collected at Hongtudi in the Dongchuan Prefecture, Yunnan province, China, in September 2013. The plant was identified by Dr. En-De Liu, and a voucher specimen 20130902 has been deposited at the Kunming Institute of Botany, China.

#### 2.3 Extraction and isolation

The fruits of *H. henryi* (20.0 kg) were powdered and percolated with MeOH at room temperature and filtered. The filtrate was evaporated in vacuo to be concentrated. The crude extract (5.4 kg) was subjected to a silica gel column chromatography (CC) eluted with CHCl<sub>3</sub> to afford a fraction (840 g). This fraction was separated over a MCI-gel column (MeOH-H<sub>2</sub>O, from 7:3 to 10:0) to produce seven fractions (Fr. A–G). Fr. A (120 g) was then chromatographed on a silica gel column, eluted with petroleum ether-acetone (from 200:1 to 0:1), to yield eight fractions (Fr. A1–A8). Fr. A3 (26.0 g) was separated over a RP-18 silica column (MeOH-H<sub>2</sub>O, from 80:20 to 100:0) to obtained four fractions (Fr. A3a–A3d). Fr. A3b (5.6 g) was further isolated by Sephadex LH-20 CC (CHCl<sub>3</sub>-MeOH, 1:1), preparative TLC, and semipreparative HPLC, to afford **1** (32 mg), **2** (14 mg), 7 (12 mg), and **8** (2.3 g). Fr. B (64 g) was chromatographed on a silica gel column, eluted with petroleum ether-acetone (from 50:1 to 0:1), to yield four fractions (Fr. B1–B4). Fr. B2 (16.2 g) was separated over a RP-18 silica column (MeOH-H<sub>2</sub>O, from 70:30 to 100:0) to obtained four fractions (Fr. B2a–B2d). Compound **3** (18 mg), **4** (21 mg), **5** (9 mg), **6** (8 mg), furohyperforin (460 mg), uralodin A (320 mg), and plukenetione B (23 mg) were obtained from Fr. B2a (4.1 g), hyphenrone M (11 mg), hyphenrone N (18 mg), tomoeone A (33 mg), and tomoeone E (14 mg) were from Fr. B2b (2.2 g), by further preparative TLC and semipreparative HPLC. Hyphenrone R (1): colorless gum;  $[\alpha]^{17}{}_{\rm D}$  –15 (*c* 0.15, MeOH); UV (MeOH)  $\lambda_{\rm max}$  (log $\varepsilon$ ) 202 (3.87), 253 (3.44), 292 (2.62) nm; IR (KBr)  $\nu_{\rm max}$  3440, 3432, 2968, 2925, 1738, 1709, 1672, 1631, 1452, 1382, 1113, 597 cm<sup>-1</sup>; circular dichroism (CD) (0.0012 M, MeOH)  $\lambda_{\rm max}$  ( $\Delta \varepsilon$ ) 203 (+1.5), 217 (–1.6), 257 (–2.7), 291 (–1.1), 332 (+1.4) nm; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; negative ESIMS *m*/*z* 583 [M–H]<sup>-</sup>; HRTOFMS *m*/*z* 607.3400 (calcd for C<sub>38</sub>H<sub>48</sub>O<sub>5</sub>Na, 607.3399). Hyphenrone S (2): colorless gum;  $[\alpha]^{18}{}_{\rm D}$  –14 (*c* 0.12, MeOH); UV (MeOH)  $\lambda_{\rm max}$  (log $\varepsilon$ ) 203 (4.42), 253 (3.96), 288

(3.16) nm; IR (KBr) v<sub>max</sub> 3441, 2970, 2928, 1738, 1709,

Table 1  $^{13}$ C NMR spectroscopic data for compounds 1–7 ( $\delta$  in ppm, 150 MHz)

		-					
No.	1 <sup>a)</sup>	<b>2</b> <sup>a)</sup>	<b>3</b> <sup>a)</sup>	<b>4</b> <sup>a)</sup>	5 <sup>a)</sup>	<b>6</b> <sup>a)</sup>	7 <sup>b)</sup>
1	71.1, C	70.8, C	77.4, C	76.6, C	77.2, C	74.2, C	80.9, C
2	205.0, C	205.0, C	206.8, C	206.3, C	206.4, C	207.8, C	195.4, C
3	69.8, C	69.8, C	97.5, C	98.0, C	96.9, C	98.9, C	117.2, C
4	215.6, C	215.5, C	209.9, C	208.9, C	209.1, C	209.3, C	175.7, C
5	72.2, C	72.3, C	49.6, C	53.1, C	48.3, C	58.7, C	60.6, C
6	91.1, C	91.1, C	35.1, CH <sub>2</sub>	33.0, CH <sub>2</sub>	34.7, CH <sub>2</sub>	33.6, CH <sub>2</sub>	38.5, CH <sub>2</sub>
7	199.8, C	199.7, C	46.8, CH	46.5, CH	46.2, CH	44.0, CH	44.4, CH
8	137.3, C	137.3, C	45.1, C	45.0, C	44.7, C	46.5, C	51.0, C
9	127.9, CH	127.9, CH	110.0, C	109.9, C	109.6, C	109.1, C	206.2, C
10	127.7 CH	127.7 CH	210.0, C	210.1, C	208.2, C	215.3, C	195.6, C
11	134.8, CH	134.8, CH	44.3, CH	44.3, CH	50.4, CH	42.3, CH	138.4, C
12	124.8, CH	124.8, CH	21.0, CH <sub>3</sub>	21.1, CH <sub>3</sub>	16.6, CH <sub>3</sub>	19.7, CH <sub>3</sub>	129.2, CH
13	152.3, C	152.3, C	19.6, CH <sub>3</sub>	19.7, CH <sub>3</sub>	28.0, CH <sub>2</sub>	19.1, CH <sub>3</sub>	128.9, CH
14	24.4, CH <sub>2</sub>	24.4, CH <sub>2</sub>			11.5, CH <sub>3</sub>		133.2, CH
15	120.4, CH	120.4, CH					128.9, CH
16	134.9, C	134.9, C					129.2, CH
17	26.2, CH <sub>3</sub>	26.2, CH <sub>3</sub>	24.1, CH <sub>2</sub>	24.1, CH <sub>2</sub>	23.9, CH <sub>2</sub>	24.5, CH <sub>2</sub>	23.0, CH <sub>2</sub>
18	17.9, CH <sub>3</sub>	18.0, CH <sub>3</sub>	117.1, CH	116.9, CH	116.8, CH	117.1, CH	121.9, CH
19	34.3, CH <sub>2</sub>	34.2, CH <sub>2</sub>	137.8, C	138.1, C	137.0, C	137.3, C	133.6, C
20	64.7, CH	64.9, CH	26.0, CH <sub>3</sub>	26.1, CH <sub>3</sub>	26.3, CH <sub>3</sub>	25.9, CH <sub>3</sub>	25.9, CH <sub>3</sub>
21	48.4, C	48.5, C	18.0, CH <sub>3</sub>	18.2, CH <sub>3</sub>	18.1, CH <sub>3</sub>	18.1, CH <sub>3</sub>	17.9, CH <sub>3</sub>
22	16.4, CH <sub>3</sub>	16.4, CH <sub>3</sub>	31.3, CH <sub>2</sub>	31.9, CH <sub>2</sub>	30.7, CH <sub>2</sub>	122.3, CH	30.5, CH <sub>2</sub>
23	54.3, CH	54.2, CH	69.0, CH	69.1, CH	68.6, CH	142.7, CH	74.0, CH <sub>2</sub>
24	130.9, CH	134.3, CH	80.4, C	81.3, C	79.9, C	71.4, C	
25	139.3, CH	135.6, CH	27.9, CH <sub>3</sub>	29.0, CH <sub>3</sub>	27.6, CH <sub>3</sub>	29.9, CH <sub>3</sub>	
26	70.9, C	82.5, C	25.9, CH <sub>3</sub>	21.0, CH <sub>3</sub>	26.3, CH <sub>3</sub>	29.6, CH <sub>3</sub>	
27	30.3, CH <sub>3</sub>	25.1, CH <sub>3</sub>	28.8, CH <sub>2</sub>	28.7, CH <sub>2</sub>	28.5, CH <sub>2</sub>	29.1, CH <sub>2</sub>	28.2, CH <sub>2</sub>
28	29.9, CH <sub>3</sub>	24.8, CH <sub>3</sub>	123.9, CH	123.6, CH	123.7, CH	123.4, CH	123.4, CH
29	27.7, CH <sub>2</sub>	27.7, CH <sub>2</sub>	133.9, C	134.3, C	133.2, C	134.6, C	134.7, C
30	126.7, CH	126.6, CH	26.1, CH <sub>3</sub>	25.9, CH <sub>3</sub>	25.9, CH <sub>3</sub>	26.1, CH <sub>3</sub>	26.0, CH <sub>3</sub>
31	132.3, C	132.3, C	18.2, CH <sub>3</sub>	17.8, CH <sub>3</sub>	17.9, CH <sub>3</sub>	18.1, CH <sub>3</sub>	18.1, CH <sub>3</sub>
32	25.9, CH <sub>3</sub>	25.9, CH <sub>3</sub>	15.3, CH <sub>3</sub>	13.8, CH <sub>3</sub>	13.4, CH <sub>3</sub>	15.3, CH <sub>3</sub>	14.7, CH <sub>3</sub>
33	18.4, CH <sub>3</sub>	18.4, CH <sub>3</sub>	39.1, CH <sub>2</sub>	39.2, CH <sub>2</sub>	38.3, CH <sub>2</sub>	38.6, CH <sub>2</sub>	37.9, CH <sub>2</sub>
34	29.6, CH <sub>2</sub>	29.6, CH <sub>2</sub>	26.6, CH <sub>2</sub>	26.6, CH <sub>2</sub>	26.1, CH <sub>2</sub>	25.5, CH <sub>2</sub>	26.0, CH <sub>2</sub>
35	58.8, CH	58.8, CH	125.9, CH	125.8, CH	125.7, CH	125.4, CH	125.7, CH
36	38.4, C	38.4, C	132.0, C	132.1, C	131.3, C	132.5, C	132.1, C
37	30.3, CH <sub>3</sub>	30.3, CH <sub>3</sub>	26.1, CH <sub>3</sub>	26.0, CH <sub>3</sub>	25.8, CH <sub>3</sub>	26.0, CH <sub>3</sub>	26.0, CH <sub>3</sub>
38	27.0, CH <sub>3</sub>	27.0, CH <sub>3</sub>	17.8, CH <sub>3</sub>	18.0, CH <sub>3</sub>	17.7, CH <sub>3</sub>	17.9, CH <sub>3</sub>	17.9, CH <sub>3</sub>

a) Recorded in methanol- $d_4$ ; b) recorded in acetone- $d_6$ .

**Table 2** <sup>1</sup>H NMR spectroscopic data for compounds 1–7 (600 MHz,  $\delta$  in ppm, J in Hz)

No.	1 <sup>a)</sup>	<b>2</b> <sup>a)</sup>	3 a)	4 <sup>a)</sup>	<b>5</b> <sup>a)</sup>	<b>6</b> <sup>a)</sup>	7 <sup>b)</sup>
6			2.30, t (13.8)	1.75, overlap	2.43, t (13.8)	1.89, dd (14.2, 3.5)	2.16, dd (13.8, 4.3)
			1.75, overlap	1.69, overlap	1.67, overlap	1.50, m	1.71, overlap
7			0.70, m	0.75, m	0.74, m	0.92, m	1.81, m
9	7.68, d (7.8)	7.68, d (7.8)					
10	7.36, t (7.8)	7.36, t (7.8)					
11	7.57, t (7.8)	7.57, t (7.8)	3.02, sept (6.5)	3.00, sept (6.5)	2.80, m	3.08, sept (6.5)	
12	7.44, d (7.8)	7.44, d (7.8)	0.90, d (6.5)	0.90, d (6.5)	1.12, d (6.6)	1.02, d (6.5)	7.43, d (7.8)
13			1.10, d (6.5)	1.10, d (6.5)	1.53, m 1.18, m	0.99, d (6.5)	7.26, t (7.8)
14	2.46, dd (15.7, 9.7)	2.46, overlap			0.81, t (7.4)		7.42, t (7.8)
	2.21, overlap	2.21, overlap					
15	5.00, m	4.99, m					7.26, t (7.8)
16							7.43, d (7.8)
17	1.67, s	1.67, s	2.64, dd (15.2, 7.5)	2.66, dd (15.2, 7.5)	2.63, dd (15.4, 7.5)	2.69, dd (15.4, 7.4)	3.06, dd (14.0, 7.5)
			2.54, dd (15.2, 7.5)	2.59, dd (15.2, 7.5)	2.56, dd (15.5, 7.5)	2.56, dd (15.4, 7.4)	2.98, dd (14.0, 7.5)
18	1.57, s	1.57, s	5.11, t (7.5)	5.11, t (7.5)	5.11, t (7.5)	5.05, overlap	5.11, t (7.5)
19	1.89, dd (11.4, 7.9)	1.91, dd (11.2, 7.6)					
	1.78, overlap	1.77, overlap					
20	2.43, m	1.57, s	1.68, s	1.69, s	1.67, s	1.65, s	1.64, s
21			1.66, s	1.67, s	1.66, s	1.65, s	1.63, s
22	1.30, s	1.29, s	2.05, overlap	1.84, t (12.8)	2.12, overlap	5.81, d (16.1)	2.67, m
			1.69, overlap	1.54, dd (12.8, 4.0)	1.71, overlap		2.01, dd (13.0, 5.6)
23	1.78, overlap	1.79, dd (8.6, 3.1)	3.73, m	3.71, dd (12.8, 4.0)	3.84, m	5.61, d (16.1)	4.71, t (9.4)
							4.56, m
24	5.64, dd (15.5, 9.4)	5.66, dd (15.7, 9.3)					
25	5.45, d (15.5)	5.46, d (15.6)	1.43, s	1.34, s	1.47, s	1.24, s	
26			1.30, s	1.37, s	1.34, s	1.24, s	
27	1.27, s	1.29, s	2.07, overlap	2.09, m	2.08, overlap	2.13, m	2.21, m
			1.68, overlap	1.76, overlap	1.74, m	1.75, m	1.89, m
28	1.27, s	1.29, s	4.90, t (7.3)	4.92, overlap	4.92, t (6.9)	4.90, overlap	5.06, overlap
29	2.14, m	2.15, m					
	1.60, overlap	1.63, overlap					
30	4.87, m	4.88, m	1.68, s	1.69, s	1.66, s	1.70, s	1.71, s
31			1.56, s	1.57, s	1.55, s	1.58, s	1.61, s
32	1.65, s	1.66, s	1.29, s	1.24, s	1.34, s	1.13, s	1.17, s
33	1.62, s	1.61, s	1.72, m	1.71, m	1.81, m	1.72, m	2.07, td (13.2, 4.3)
			1.28, m	1.28, m	1.34, overlap	1.47, m	1.49, m
34	2.21, overlap	2.21, overlap	2.06, m	2.03, m	2.11, overlap	2.16, m	2.20, overlap
	1.94, dd (11.6, 8.8)	1.94, dd (11.3, 7.8)	1.87, m	1.87, m	1.94, m	1.89, m	2.01, overlap
35	2.62, t (8.8)	2.62, dd (9.2, 8.3)	5.01, t (7.3)	5.01, t (7.3)	5.04, t (7.5)	5.02, overlap	5.05, overlap
37	1.14, s	1.14, s	1.65, s	1.65, s	1.62, s	1.67, s	1.66, s
38	1.35, s	1.35, s	1.57, s	1.67, s	1.57, s	1.59, s	1.63, s

a) Recorded in methanol- $d_4$ ; b) recorded in acetone- $d_6$ .

1673, 1631, 1452, 1383, 1114, 574 cm<sup>-1</sup>; CD (0.0005 M, MeOH)  $\lambda_{max}$  ( $\Delta \varepsilon$ ) 204 (+3.0), 217 (-4.2), 257 (-8.9), 294 (-3.5), 331 (+4.4) nm; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; positive ESIMS *m/z* 623 [M+Na]<sup>+</sup>; HRTOFMS *m/z* 623.3351 (calcd for C<sub>38</sub>H<sub>48</sub>O<sub>6</sub>Na, 623.3349).

Hyphenrone T (**3**): colorless crystal; m.p. 146–148 °C;  $[\alpha]^{19}_{D}$  –118 (*c* 0.09, MeOH); UV (MeOH)  $\lambda_{max}$  (log $\varepsilon$ ) 202 (4.38) nm; IR (KBr)  $\nu_{max}$  3453, 2968, 2929, 1774, 1742, 1710, 1635, 1448, 1383, 1171, 1058 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; positive ESIMS *m*/*z* 591 [M+Na]<sup>+</sup>; HRTOFMS *m*/*z* 591.3656 (calcd for C<sub>35</sub>H<sub>52</sub>O<sub>6</sub>Na, 591.3662).

Hyphenrone U (4): colorless gum;  $[\alpha]^{19}{}_{D}$  –46 (*c* 0.16, MeOH); UV (MeOH)  $\lambda_{max}$  (log $\varepsilon$ ) 202 (4.02) nm; IR (KBr)  $\nu_{max}$  3563, 3440, 2972, 2931, 1775, 1743, 1718, 1629, 1447, 1381, 1083, 1231, 1200, 1054 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; positive ESIMS *m*/*z* 591 [M+Na]<sup>+</sup>; HRTOFMS *m*/*z* 591.3653 (calcd for C<sub>35</sub>H<sub>52</sub>O<sub>6</sub>Na, 591.3662).

Hyphenrone V (5): colorless gum;  $[\alpha]^{21}_{D}$  –38 (*c* 0.16, MeOH); UV (MeOH)  $\lambda_{max}$  (log $\varepsilon$ ) 202 (4.18) nm; IR (KBr)  $\nu_{max}$  3456, 3441, 2971, 2930, 1774, 1741, 1631, 1452, 1383, 1114, 1052 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; positive ESIMS *m*/*z* 583 [M+H]<sup>+</sup>; HRTOFMS *m*/*z* 605.3817 (calcd for C<sub>36</sub>H<sub>54</sub>O<sub>6</sub>Na, 605.3818).

Hyphenrone W (6): colorless gum;  $[\alpha]^{17}_{D}$  +6 (*c* 0.08, MeOH); UV (MeOH)  $\lambda_{max}$  (log $\varepsilon$ ) 202 (3.97) nm; IR (KBr)  $\nu_{max}$  3443, 2972, 2929, 1730, 1709, 1631, 1449, 1384, 1153, 1115 cm<sup>-1</sup>; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; positive ESIMS *m/z* 591 [M+Na]<sup>+</sup>; HRTOFMS *m/z* 591.3661 (calcd for C<sub>35</sub>H<sub>52</sub>O<sub>6</sub>Na, 591.3662).

Hyphenrone X (7): colorless crystal; m.p. 124–126 °C;  $[\alpha]^{21}_{D}$  –23 (*c* 0.18, MeOH); UV (MeOH)  $\lambda_{max}$  (log $\varepsilon$ ) 202 (4.42), 248 (4.16), 274 (4.05) nm; IR (KBr)  $v_{max}$  2971, 2930, 1739, 1710, 1672, 1632, 1453, 1383, 1115 cm<sup>-1</sup>; CD (0.0002 M, MeOH)  $\lambda_{max}$  ( $\Delta \varepsilon$ ) 201 (+15.9), 246 (+11.1), 270 (–21.8), 300 (+3.8) nm; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1 and Table 2; positive ESIMS *m*/*z* 551 [M+Na]<sup>+</sup>; HRTOFMS *m*/*z* 551.3129 (calcd for C<sub>35</sub>H<sub>44</sub>O<sub>4</sub>Na, 551.3137).

Crystallographic data of **3**: C<sub>35</sub>H<sub>52</sub>O<sub>6</sub>, *M*=568.77, orthorhombic, *a*=9.4718(2) Å, *b*=14.3354(4) Å, *c*=23.4620(6) Å, *α*=90.00°, *β*=90.00°, *γ*=90.00°, *V*=3185.72(14) Å<sup>3</sup>, *T*=100(2) K, space group *P*212121, *Z*=4,  $\mu$ (Cu-K $\alpha$ )=0.628 mm<sup>-1</sup>, 16002 reflections measured, 5583 independent reflections (*R*<sub>int</sub>=0.0797). The final *R*<sub>1</sub> values were 0.0666 (*I*>2 $\sigma$ (*I*)). The final *wR*(*F*<sup>2</sup>) values were 0.1771 (*I*>2 $\sigma$ (*I*)). The final *R*<sub>1</sub> values were 0.0863 (all data). The final *wR*(*F*<sup>2</sup>) values were 0.2217 (all data). The goodness of fit on *F*<sup>2</sup> was 1.211. Flack parameter=0.2(3). The Hooft parameter is 0.19(16) for 2331 Bijvoet pairs. Crystallographic data for **3** have been deposited at the Cambridge Crystallographic Data Center (deposition number CCDC 1448224). Copies of the data can be obtained free of charge via www.ccdc.cam.ac.uk.

Crystallographic data of 7:  $C_{35}H_{44}O_4$ , *M*=528.70, orthorhombic, *a*=8.8788(2) Å, *b*=11.3127(3) Å, *c*=29.3926(7) Å,  $\alpha$ =90.00°,  $\beta$ =90.00°,  $\gamma$ =90.00°, V=2952.29(12) Å<sup>3</sup>, T=100(2) K, space group *P*212121, *Z*=4,  $\mu$ (Cu-K $\alpha$ )=0.595 mm<sup>-1</sup>, 14377 reflections measured, 5052 independent reflections ( $R_{int}$ =0.0839). The final  $R_1$  values were 0.0487 (I>2 $\sigma$ (I)). The final  $wR(F^2)$  values were 0.1367 (I>2 $\sigma$ (I)). The final  $wR(F^2)$  values were 0.1367 (I>2 $\sigma$ (I)). The final  $R_1$  values were 0.0936 (all data). The final  $wR(F^2)$  values were 0.1795 (all data). The goodness of fit on  $F^2$  was 1.061. Flack parameter=0.0(2). The Hooft parameter is -0.07(10) for 2071 Bijvoet pairs. (CCDC 1448225).

#### 2.4 Cytotoxicity bioassays

Colorimetric assays were performed to evaluate compound activity. The following human tumor cell lines were used: HL-60 human myeloid leukemia, SMMC-7721 human hepatocarcinoma, A-549 lung cancer, MCF-7 breast cancer, and SW-480 human pancreatic carcinoma. All cells were cultured in RPMI-1640 or DMEM medium (Hyclone, Logan, UT), supplemented with 10% fetal bovine serum (Hyclone) at 37 °C in a humidified atmosphere with 5% CO<sub>2</sub>. Cell viability was assessed by conducting colorimetric measurements of the amount of insoluble formazan formed in living cells based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT). Briefly, 100 µL adherent cells were seeded into each well of a 96-well cell culture plate and allowed to adhere for 12 h before test compound addition, while suspended cells were seeded just before this step, both with initial density of  $1 \times 10^5$  cells/mL in 100 µL of medium. Each tumor cell line was exposed to the test compound at various concentrations in triplicate for 48 h, with cis-platin (Sigma, USA) as positive control. After the incubation, MTT (100 µg) was added to each well, and the incubation continued for 4 h at 37 °C. The cells were lysed with 100 µL of 20% sodium dodecyl sulfate (SDS)-50% DMF after removal of 100 µL of medium. The optical density of the lysate was measured at 595 nm in a 96-well microtiter plate reader (Bio-Rad 680, USA). The IC<sub>50</sub> value of each compound was calculated by Reed and Muench's method.

### **3** Results and discussion

Hyphenrone R (1) was obtained as colorless gum and possessed a molecular formula  $C_{38}H_{48}O_5$  as established by <sup>13</sup>C NMR and HRTOFMS data (*m/z* 607.3400, [M+Na]<sup>+</sup>), indicating 15 degrees of unsaturation. The IR spectrum showed absorption bands due to hydroxyl (3440 and 3432 cm<sup>-1</sup>), carbonyl groups (1738, 1709, and 1672 cm<sup>-1</sup>), and an aromatic ring (1598 and 1446 cm<sup>-1</sup>). The <sup>1</sup>H NMR spectrum (Table 1) exhibited four olefinic protons ( $\delta_H$  4.87, 5.00, 5.45, and 5.64), an *ortho*-disubstituted benzene moiety ( $\delta_H$  7.68, d; 7.36, t; 7.57, t; 7.44, d, *J*=7.8 Hz), and nine singlet methyls ( $\delta_H$  1.14–1.67). The <sup>13</sup>C and distortionless enhancement by polarization transfer (DEPT) spectra displayed 38 carbon

resonances (Table 2) attributable to twelve quaternary carbons (including three carbonyls), nine methines (including six olefinic ones), two methylenes, five methyls, and 10 other resonances assignable to two prenyl groups. Analysis of these data indicated the characteristic signals of three ketones  $(\delta_{\rm C} 205.0, {\rm C-2}; 215.6, {\rm C-4}; 199.8, {\rm C-7})$  and six quaternary carbons (δ<sub>C</sub> 71.1, C-1; 69.8, C-3; 72.2, C-5; 91.1, C-6; 48.4, C-21; 38.4, C-36) for a caged PPAP, such as hyperuralone B [16]. Further comparison of the 1D NMR spectroscopic data of 1 with those of hyperuralone B revealed that they were structurally similar. The signals for two methylenes ( $\delta_{\rm C}$ 38.7, C-22; 42.0, C-23) in hyperuralone B were replaced by a methyl at  $\delta_{\rm C}$  16.4 (C-22) and a methine at  $\delta_{\rm C}$  54.3 (C-23) in 1, which suggested that one isoprenyl unit was connected to C-23 in 1 rather than C-22 in hyperuralone B. This assumption was evidenced by the correlations from Me-22 ( $\delta_{\rm H}$ 1.30, s) to C-6, C-20 ( $\delta_{\rm C}$  64.7), C-21, and C-23, from H<sub>2</sub>-29 ( $\delta_{\rm H}$  2.14 and 1.60) to C-3 and C-23 in the heteronuclear multiple bond correlation (HMBC) spectrum. Furthermore, an oxygenated isoprenyl group ( $\delta_{\rm C}$  130.9, C-24; 139.3, C-25; 70.9, C-26; 30.0, C-27; 29.9, C-28) was connected to C-20 by the HMBC correlations from both Me-27 and Me-28 ( $\delta_{\rm H}$ 1.27, s) to C-25 and C-26, and from H-24 ( $\delta_{\rm H}$  5.64) to C-19 ( $\delta_{\rm C}$  34.3), C-20, and C-21, coupled with the proton spin system of H-25/H-24/H-20 in the 1H-1H COSY spectrum (Figure 1). The rest part of the structure of 1 was determined to be the same as that of hyperuralone B by analysis of the 2D NMR spectroscopic data. The correlations of Me-22/H<sub>2</sub>-29, Me-22/H-24/H-19β/H-34β, and H-34α/H-35 in the ROESY spectrum, in combination with the rigid caged carbon skeleton, defined the relative configuration of 1. Since the absolute configuration of hyperuralone B has been established by ECD calculation [16], the well matched experimental CD curves of 1 and hyperuralone B in Figure 2 suggested the absolute configuration of 1 to be 1S,3S,5R,6S,20R,21S,23S,35S.

Hyphenrone S (2) shared the same carbon skeleton and absolute configuration of 1 by analysis of its 1D (Table 1 and Table 2) and 2D NMR spectroscopic data, as well as its CD data (Figure 2). The increased 16 mass units of the molecular weight (m/z 623.3351, [M+Na]<sup>+</sup>) observed in HRTOFMS and 11.6 ppm downshift of C-26 ( $\delta_C$  82.5) in the <sup>13</sup>C NMR spectra of 2 indicated that the hydroxyl in 1 was replaced by a hydroperoxyl in 2 [17].

Hyphenrone T (**3**) was isolated as a colorless gum. Its molecular formula was established from the <sup>13</sup>C NMR and HRTOFMS data (*m/z* 591.3656, [M+Na]<sup>+</sup>) as C<sub>35</sub>H<sub>52</sub>O<sub>6</sub>, indicating ten degrees of unsaturation. The <sup>1</sup>H NMR spectrum showed signals assignable to a isopropyl ( $\delta_{\rm H}$  1.10, 3H, d; 0.90, 3H, d; 3.02, 1H, sept, *J*=6.5 Hz), three olefinic protons ( $\delta_{\rm H}$ 5.11, 5.01, and 4.90), and other nine singlet methyl groups ( $\delta_{\rm H}$  1.29–1.68). The <sup>13</sup>C and DEPT NMR spectra exhibited 35 carbon resonances (Table 2) attributable to eight quater-



Figure 1 Key HMBC, <sup>1</sup>H-<sup>1</sup>H COSY, and ROESY correlations of 1 (color online).



Figure 2 The experimental CD spectra of 1, 2, and hyperuralone B.

nary carbons (including three carbonyls), two methines, three methylenes, three methyls, and 19 other resonances assignable to one isobutyryl and three prenyl groups. The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data of **3** were resemble to those of 3-hydroxyhyperforin-3,9-hemi-ketal (8) [11], a bicyclic polyprenylated acylphloroglucinols (BPAP) with a bicyclo[3.3.1]nonane-2,4,9-trione core, indicating that they are structural similar. However, the double bond of the isoprenyl group at C-5 in the known compound was oxidized  $(\delta_{\rm C} 69.0, \text{C-23}; 80.4, \text{C-24})$  in **3**, as evidenced by the HMBC correlations of Me-25 ( $\delta_{\rm H}$  1.43) and Me-26 ( $\delta_{\rm H}$  1.30) with C-23 and C-24, and of H<sub>2</sub>-22 ( $\delta_{\rm H}$  2.05 and 1.69) with C-4  $(\delta_{\rm C} 209.9)$ , C-5  $(\delta_{\rm C} 49.6)$ , and C-9  $(\delta_{\rm C} 110.0)$ . An oxygen bridge between C-9 and C-13 was expected by the downfield chemical shifts of C-9 ( $\delta_{\rm C}$  110.0) and C-24 ( $\delta_{\rm C}$  80.4) and the degree of unsaturation, which put C-9 in a state of ketal. Other parts of 3 were identical to those of 8 by analysis of the 2D NMR spectroscopic data. The final refinement on the Cu-Ka data (CCDC 1448224) of the crystal of 3 (the Flack parameter is 0.2(3); the Hooft parameter is 0.19(16) for 2331 Bijvoet pairs) allowed an unambiguous assignment of the absolute configuration as 1R,3R,5S,7S,8R,9S,23R (Figure 3).

Hyphenrone U (4) shared the same planar scaffold as 3 by detailed analysis of its HRTOFMS, 1D and 2D NMR spectroscopic data. The <sup>13</sup>C NMR data of 4 (Table 2) were nearly the same to those of 3 except for the carbon resonances of C-5, C-6, C-25 and C-26, which supposed 4 as 23-epimer of

**3**. The correlation of H-23 (3.71) with H-6 ( $\delta_{\rm H}$  1.75) in the ROESY spectrum (Figure 4) confirmed that a  $\beta$ -OH was substituted at C-23.

The molecular formula of hyphenrone V (**5**) was determined as C<sub>36</sub>H<sub>54</sub>O<sub>6</sub> by analysis of its <sup>13</sup>C NMR (Table 2) and HRTOFMS data (m/z 605.3817, [M+Na]<sup>+</sup>), 14 mass units more than that of **3**. Comparison of the <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data of **5** with those of **3** indicated that the isopropyl group in **3** is replaced by a *sec*-butyl group (C-11,  $\delta_C$ 50.4; C-12,  $\delta_C$  16.6; C-13,  $\delta_C$  28.0; and C-14,  $\delta_C$  11.5) in **5**. Other parts of **5** were identical to those of **3** by analysis of the 2D NMR spectroscopic data.

Hyphenrone W (6) was assigned the molecular formula  $C_{36}H_{54}O_6$  from its <sup>13</sup>C NMR and HREIMS data. The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data of 6 (Table 1 and Table 2) resembled those of 8. Instead of the olefinic quaternary carbon at  $\delta_C$  133.5 (C-24) and a methylene ( $\delta_C$  31.7, C-22) in 8, an



Figure 3 Single-crystal X-ray structures of 3 and 7 (color online).



Figure 4 Key HMBC, <sup>1</sup>H-<sup>1</sup>H COSY, and ROESY correlations of 3 and 4 (color online).

Table 3 Cytotoxicities of selected PPAPs against five cancer cell lines (IC\_{50} in  $\mu M)$ 

Com- pound <sup>a)</sup>	HL-60	SMMC- 7721	A-549	MCF-7	SW-480
1	3.3	22.1	17.6	16.2	22.5
4	6.1	13.7	12.6	5.5	16.2
5	13.8	19.8	17.0	13.1	>40
7	4.3	22.8	11.5	2.1	23.3
<i>cis-</i> Platin <sup>b)</sup>	2.3	10.0	8.3	14.7	15.1
Taxol <sup>b)</sup>	< 0.008	< 0.008	< 0.008	< 0.008	< 0.008

a) Other isolates with  $IC_{s0}>40 \mu M$  for all cell lines are not listed; b) *cis*platin and taxol were used as positive controls. oxygenated quaternary carbon at  $\delta_{\rm C}$  71.4 and an olefinic methine ( $\delta_{\rm C}$  122.3) appeared in **6**, assuming hydroxylation of C-24 and formation of a  $\Delta^{22,23}$  double bond. This assumption was supported by the correlations of H-22 ( $\delta_{\rm H}$  5.81, *J*=16.1 Hz) with C-4 ( $\delta_{\rm C}$  209.3), C-5, ( $\delta_{\rm C}$  58.7), and C-9 ( $\delta_{\rm C}$  109.1), and of both Me-25 and Me-26 ( $\delta_{\rm H}$  1.24) with C-23 ( $\delta_{\rm C}$  142.7) and C-24 in the HMBC spectrum. The 2D NMR data showed that other structural units of **6** are the same as those of **8**.

On the basis of analysis of its MS, 1D, and 2D NMR data (Table 1 and Table 2), hyphenrone X (7) was shown to possess the same backbone and relative configuration as deoxy-furohyperforin A [18], a PPAP isolated from *H. perforatum* in 2003. The structural novelty of 7 involves the presence of a phenyl attached to C-10 rather than an isopropyl group. The final refinement on the Cu-K $\alpha$  data (CCDC 1448225) of the crystal of 7 (the Flack parameter is 0.0(2); the Hooft parameter is -0.07(10) for 2071 Bijvoet pairs) allowed an unambiguous assignment of the absolute configuration as 1*R*,5*S*,7*S*,8*R* (Figure 3).

Considering the fact that several cytotoxic PPAPs have been isolated previously [7,9,19,20], the inhibitory activities of the new compounds were examined against five human tumor cell lines HL-60, A-549, SMMC-7721, MCF-7, and SW-480. As shown in Table 3, compounds 1, 4, 5, and 7 exhibited moderate cytotoxic activities (IC<sub>50</sub> 3.3–23.3  $\mu$ M) against the cancer cell lines using the MTT method [21].

Acknowledgments This work was supported by the Natural Sciences Foundation of Yunnan Province (2015FA032), Foundation of State Key Laboratory of Phytochemistry and Plant Resources in West China (P2015-ZZ07), the foundation from Youth Innovation Promotion Association CAS to X.W. Yang and G. Xu, and the West Light Foundation of the Chinese Academy of Sciences to X.W. Yang.

**Conflict of interest** The authors declare that they have no conflict of interest.

Supporting information The original MS, <sup>1</sup>H and <sup>13</sup>C NMR, HSQC, <sup>1</sup>H-<sup>1</sup>H COSY, HMBC, and ROESY NMR spectra of compounds **1**–7, and crystallographic files for **3** and **7** in CIF format. The supporting information is available online at http://chem.scichina.com and http://link.springer.com/journal/11426. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.

- 1 Ciochina R, Grossman RB. Chem Rev, 2006, 106: 3963-3986
- 2 Sparling BA, Moebius DC, Shair MD. J Am Chem Soc, 2013, 135: 644–647
- 3 Grenning AJ, Boyce JH, Porco JA. J Am Chem Soc, 2014, 136: 11799–11804
- 4 Griffith T, Varela-Nallar L, Dinamarca M, Inestrosa N. Curr Med Chem, 2010, 17: 391–406
- 5 Adam P, Arigoni D, Bacher A, Eisenreich W. *J Med Chem*, 2002, 45: 4786–4793
- 6 Nualkaew N, Morita H, Shimokawa Y, Kinjo K, Kushiro T, De-Eknamkul W, Ebizuka Y, Abe I. *Phytochemistry*, 2012, 77: 60–69
- 7 Yang XW, Li MM, Liu X, Ferreira D, Ding Y, Zhang JJ, Liao Y, Qin

HB, Xu G. J Nat Prod, 2015, 78: 885-895

- 8 Lan M. Jinsitao In: Wu ZY, Gao L, Eds. South Yunnan Materia Medica. Volume 1. Kunming: Science Press, 2008. 236–240
- 9 Yang XW, Ding Y, Zhang JJ, Liu X, Yang LX, Li XN, Ferreira D, Walker LA, Xu G. Org Lett, 2014, 16: 2434–2437
- 10 Zhang JJ, Yang XW, Ma JZ, Ye Y, Shen XL, Xu G. *Tetrahedron*, 2015, 71: 8315–8319
- Verotta L, Appendino G, Jakupovic J, Bombardelli E. *J Nat Prod*, 2000, 63: 412–415
- 12 Verotta L, Appendino G, Belloro E, Jakupovic J, Bombardelli E. J Nat Prod, 1999, 62: 770–772
- 13 Guo N, Chen XQ, Zhao QS. Acta Bot Yunnan, 2008, 30: 515-518
- 14 Henry GE, Jacobs H, Carrington CMS, McLean S, Reynolds WF. *Tetrahedron*, 1999, 55: 1581–1596

- 15 Hashida W, Tanaka N, Kashiwada Y, Sekiya M, Ikeshiro Y, Takaishi Y. *Phytochemistry*, 2008, 69: 2225–2230
- 16 Zhang JJ, Yang J, Liao Y, Yang XW, Ma JZ, Xiao QL, Yang LX, Xu G. Org Lett, 2014, 16: 4912–4915
- 17 Zhang JJ, Yang XW, Liu X, Ma JZ, Liao Y, Xu G. *J Nat Prod*, 2015, 78: 3075–3079
- 18 Vajs V, Vugdelija S, Trifunović S, Karadžić I, Juranić N, Macura S, Milosavljević S. *Fitoterapia*, 2003, 74: 439–444
- 19 Yang XW, Deng X, Liu X, Wu CY, Li XN, Wu B, Luo HR, Li Y, Xu HX, Zhao QS, Xu G. *Chem Commun*, 2012, 48: 5998–6000
- 20 Liao Y, Liu X, Yang J, Lao YZ, Yang XW, Li XN, Zhang JJ, Ding Z, Xu HX, Xu G. *Org Lett*, 2015, 17: 1172–1175
- 21 Ellman GL, Courtney KD, Andres V, Featherstone RM. *Biochem Pharmacol*, 1961, 7: 88–95